{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-019911","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2023-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.505382+00:00","generated_at":"2026-06-07T10:32:33.728448+00:00","sec_items":["2.05","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aclaris cuts workforce 46%, expects ATI-1777 Phase 2b topline data in Jan 2024","bullets":["Workforce reduction of ~46%; one-time charge ~$3.1M in Q4 2023, total costs $5.0-5.3M over 12 months.","ATI-1777 Phase 2a results published in JID Innovations; Phase 2b topline data expected January 2024.","ATI-450 (zunsemetinib) repurposed for pancreatic cancer and metastatic breast cancer in collaboration with Washington University.","ATI-2138 (ITK/JAK3) indication reassessed due to competitive landscape; guidance in early 2024.","Company accelerating discovery programs from KINect platform to generate IND applications near term."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-019911","json":"https://secwatch.observer/filing/0001558370-23-019911.json","markdown":"https://secwatch.observer/filing/0001558370-23-019911.md","text":"https://secwatch.observer/filing/0001558370-23-019911.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000155837023019911/0001558370-23-019911-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000155837023019911/acrs-20231219x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T10:32:33.728448+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ca12ae67f72a1161ef6dc25c824b95d10c3050c3","claim":"Aclaris Therapeutics, Inc. announced a restructuring with charges of totaling approximately $3.1 million (approximately 46%).","evidence_excerpt":"order to streamline operations, reduce costs and preserve capital. ​ As a result of the reduction in force, the Company expects to incur a one-time charge totaling approximately $3.1 million in connection with one-time employee termination costs, including severance and other benefits. This charge is expected to be incurred during the quarter ending December 31,","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1557746/000155837023019911/0001558370-23-019911-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"totaling approximately $3.1 million"},{"label":"Headcount","value":"approximately 46%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}